The rising technological advancements and innovations in rapid diagnostic testing which is expected to drive market expansion in the near future at a CAGR of 21.3% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Rapid Diagnostics Market” that contains information from 2023 to 2032. 

Market Highlights

The global rapid diagnostics market is accounted to register a CAGR of 21.3% during the forecast period and is estimated to reach USD 177.37 billion by 2032.

Rapid diagnostics are medical diagnostic tests that provide quick and accurate results in a short amount of time. They can be performed at point-of-care or in a laboratory setting and are used to detect and diagnose various diseases and conditions, including infectious diseases, cancers, and cardiac disorders. Rapid diagnostic testing (RDT) is mostly used in preliminary or emergency medical screening and medical facilities with limited resources.

Rapid diagnostic tests are widely used in diagnosis, medical care, epidemiology, and screening. The primary drivers of market expansion are increased demand for rapid diagnostic tests in decentralized settings and rising public awareness of the need for early diagnosis. Other factors driving the growth of the global rapid diagnostics market include increasing demand for point-of-care diagnostics, the rising prevalence of chronic diseases coupled with an aging population, the growing need for rapid decision-making in emergency departments, and emerging technological innovations. Rising demand for bedside diagnostic testing will also provide profitable growth opportunities for rapid diagnostics market share.

Key Players

MRFR recognizes the following companies as the key players in the global rapid diagnostics market— Abaxis, Becton, Dickinson & Company, Bio-Rad Laboratories, Accriva Diagnostics, ACON Laboratories Inc, Hologic Inc, Abbott Laboratories, Roche Diagnostics, Bayer HealthCare Pharmaceuticals LLC, Cepheid Inc.

Segment Analysis

The global rapid diagnostics market has been segmented based on product and application.

Based on product, the market is segmented into Over the Counter (OTC) Kits and Professional Kits. The over-the-counter (OTC) kits segment was attributed to holding the largest market share in 2022.

The global rapid diagnostics market has been segmented based on application into Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy & Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, and Toxicology Testing. The infectious disease testing segment was expected to hold the largest market share in 2022.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Rapid Diagnostics Market Research Report

Regional Analysis

Based on region, the global rapid diagnostics market has been divided into North America, Europe, Asia-Pacific, and the rest of the World. North America consists of US and Canada. The Europe rapid diagnostics market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The rapid diagnostics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world's rapid diagnostics market comprises the Middle East, Africa, and Latin America.

The North American market is the largest global market for rapid diagnostics due to the high adoption rate of advanced diagnostic technologies and the presence of major industry players. Moreover, the region's well-established healthcare infrastructure, increasing prevalence of chronic diseases, and favorable government initiatives to support the adoption of point-of-care testing are key factors driving market growth in North America.

The European market for rapid diagnostics is expected to grow significantly, attributed to the increasing demand for faster and more accurate diagnosis of infectious diseases, rising healthcare expenditure, and government initiatives to promote the adoption of point-of-care testing. The presence of advanced healthcare infrastructure and increasing awareness about the benefits of early disease diagnosis are also fueling the growth of the European market.

The Asia Pacific region is expected to witness the fastest growth in the global rapid diagnostics market owing to the increasing demand for point-of-care testing, rising healthcare expenditure, and the growing prevalence of chronic diseases. Additionally, the large patient population in the region, coupled with the increasing focus on improving healthcare access and quality, is expected to drive the growth of the rapid diagnostics market in the Asia Pacific.

Other regions, including Latin America, the Middle East, and Africa, also witness significant growth due to the increasing focus on improving healthcare access and the rising prevalence of infectious diseases. The increasing investment in the healthcare sector and the adoption of advanced diagnostic technologies are also expected to contribute to regional market growth.

Key Findings of the Study

• The global rapid diagnostics market is anticipated to reach USD 177.37 billion by 2032, at a CAGR of 21.3% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market for rapid diagnostics due to the increasing prevalence of infectious diseases, rising awareness about early disease diagnosis, growing demand for point-of-care testing, and increasing healthcare spending in countries such as India and China.


• Based on product, the over-the-counter (OTC) kits segment was attributed to holding the largest market in 2022, with an approximate market share of 61%.


• Abaxis, Becton, Dickinson & Company, Bio-Rad Laboratories, Accriva Diagnostics, ACON Laboratories Inc, Hologic Inc, Abbott Laboratories, Roche Diagnostics, Bayer HealthCare Pharmaceuticals LLC, Cepheid Inc.